Compare Aventis Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DR. DATSONS LABS - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DR. DATSONS LABS SANOFI INDIA/
DR. DATSONS LABS
 
P/E (TTM) x 38.7 -10.9 - View Chart
P/BV x 6.9 0.2 4,258.8% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 SANOFI INDIA   DR. DATSONS LABS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
DR. DATSONS LABS
Mar-14
SANOFI INDIA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs6,840126 5,445.9%   
Low Rs4,63031 14,983.8%   
Sales per share (Unadj.) Rs1,203.1133.0 904.7%  
Earnings per share (Unadj.) Rs165.30.2 109,004.5%  
Cash flow per share (Unadj.) Rs209.96.6 3,175.9%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.6128.8 748.2%  
Shares outstanding (eoy) m23.0331.66 72.7%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.80.6 810.1%   
Avg P/E ratio x34.7516.1 6.7%  
P/CF ratio (eoy) x27.311.8 230.8%  
Price / Book Value ratio x6.00.6 979.6%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,0782,477 5,331.3%   
No. of employees `0003.3NA-   
Total wages/salary Rs m4,06856 7,264.3%   
Avg. sales/employee Rs Th8,393.8NM-  
Avg. wages/employee Rs Th1,232.4NM-  
Avg. net profit/employee Rs Th1,153.0NM-  
INCOME DATA
Net Sales Rs m27,7084,211 658.1%  
Other income Rs m89779 1,139.8%   
Total revenues Rs m28,6054,289 666.9%   
Gross profit Rs m6,235569 1,096.6%  
Depreciation Rs m1,027204 502.4%   
Interest Rs m7430 1.6%   
Profit before tax Rs m6,09813 48,015.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2926 37,573.8%   
Profit after tax Rs m3,8065 79,291.7%  
Gross profit margin %22.513.5 166.6%  
Effective tax rate %37.648.0 78.3%   
Net profit margin %13.70.1 12,049.1%  
BALANCE SHEET DATA
Current assets Rs m15,9226,852 232.4%   
Current liabilities Rs m6,2356,711 92.9%   
Net working cap to sales %35.03.3 1,044.0%  
Current ratio x2.61.0 250.1%  
Inventory Days Days64161 39.6%  
Debtors Days Days21318 6.6%  
Net fixed assets Rs m7,5393,673 205.3%   
Share capital Rs m230317 72.6%   
"Free" reserves Rs m21,9623,761 583.9%   
Net worth Rs m22,1924,078 544.3%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m29,83912,633 236.2%  
Interest coverage x872.11.0 84,713.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.3 278.6%   
Return on assets %12.83.4 371.1%  
Return on equity %17.20.1 14,568.8%  
Return on capital %27.57.7 358.5%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m7,587964 787.0%   
Fx outflow Rs m7,145607 1,176.9%   
Net fx Rs m442357 123.8%   
CASH FLOW
From Operations Rs m3,7391,345 278.0%  
From Investments Rs m-731-2,256 32.4%  
From Financial Activity Rs m-1,972-1,200 164.4%  
Net Cashflow Rs m1,036-2,111 -49.1%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 1.4 1,081.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 94.1 11.2%  
Shareholders   15,184 20,807 73.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Apr 3, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS